KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $33.0 million.

  • Moderna's Capital Expenditures fell 78.15% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $675.0 million, marking a year-over-year decrease of 9.88%. This contributed to the annual value of $1.1 billion for FY2024, which is 48.66% up from last year.
  • Per Moderna's latest filing, its Capital Expenditures stood at $33.0 million for Q3 2025, which was up 1,000.00% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Capital Expenditures ranged from a high of $522.0 million in Q4 2024 and a low of $3.0 million during Q2 2025.
  • Moreover, its 3-year median value for Capital Expenditures was $151.0 million (2024), whereas its average is $173.7 million.
  • Per our database at Business Quant, Moderna's Capital Expenditures skyrocketed by 421.05% in 2021 and then crashed by 98.35% in 2025.
  • Quarterly analysis of 5 years shows Moderna's Capital Expenditures stood at $120.0 million in 2021, then fell by 23.33% to $92.0 million in 2022, then surged by 139.13% to $220.0 million in 2023, then soared by 137.27% to $522.0 million in 2024, then tumbled by 78.15% to $33.0 million in 2025.
  • Its Capital Expenditures was $33.0 million in Q3 2025, compared to $3.0 million in Q2 2025 and $117.0 million in Q1 2025.